Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICARUS: SBRT + Atezolizumab in Metastatic Cancers
NCT06416436Phase 1Withdrawn
- Sponsor
- University of Kansas Medical Center
- Start
- Jul 2024
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atezolizumab in solid tumor, sponsored by University of Kansas Medical Center. Primary endpoint: Maximum Tolerated Dose of Ultra-high Dose Stereotactic Ablative Radiotherapy at 1 month. Planned start Jul 2024; status: withdrawn.
02
Drugs
atezolizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06416436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416436.